QDEL · QuidelOrtho Corporation

Current Thesis

QuidelOrtho’s remaining recovery case requires a signed point-of-care divestiture and a weekly reclaim of the former $13.75 threshold before a weekly close below the September 18 reference close of $10.62. This is a prospective recovery test: the earlier thesis has already failed its published price condition. The September 18, 2026 close of $10.62 is below the $13.75 weekly invalidation threshold retained in the September 6 dossier.

The narrative is dead — that assessment describes the June sale-rumor leg, whose published price condition was breached by September 18. The Financial Times reported a proposed $1.5 billion valuation for the point-of-care business on June 27; a June 29 report reproduced that valuation and named interested private-equity firms. The reporting described a process, not an agreement. No subsequent definitive agreement was verified for this refresh. Financial Times reporting reproduced by CACLP, June 29, 2026.

The prospective recovery case has low conviction because the observable change since September 6 is a broken price condition, while transaction terms remain unverified. Its measurable completion requires both a signed agreement specifying cash proceeds available for debt repayment and a weekly close above $13.75 before the new $10.62 condition fires.

Bullish and bearish views on QuidelOrtho Corporation

The model's bull view on QuidelOrtho Corporation (QDEL), in brief: The business has sale interest. The June 29, 2026 reproduction of Financial Times reporting named Advent International, SK Capital Partners and Archimed as interested parties around a proposed $1.5 billion valuation. This supports the existence of reported interest; it does not… The bear view: Cash conversion remains unresolved. On August 6, 2026, management withdrew its $100–120 million full-year free-cash-flow forecast, citing working-capital effects and mitigation efforts. Adjusted profitability therefore lacks a current company cash-flow forecast behind it.… Both cases follow in full.

Bull Case

• The business has sale interest. The June 29, 2026 reproduction of Financial Times reporting named Advent International, SK Capital Partners and Archimed as interested parties around a proposed $1.5 billion valuation. This supports the existence of reported interest; it does not establish executable terms. Reported sale process.
• Underlying laboratory sales grew. QuidelOrtho reported on August 6, 2026 that second-quarter laboratory revenue outside China increased 9% year over year, both reported and at constant currency. That measured result limits the claim that weakness is uniform across the franchise. Second-quarter results.
• Operating margins improved. The August 6, 2026 release reported second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $129 million and a 20.5% margin, improving 310 basis points year over year. Those results provide operating evidence for a recovery case, subject to the price and transaction conditions above. Second-quarter results.

Bear Case

• Cash conversion remains unresolved. On August 6, 2026, management withdrew its $100–120 million full-year free-cash-flow forecast, citing working-capital effects and mitigation efforts. Adjusted profitability therefore lacks a current company cash-flow forecast behind it. Guidance update.
• The earnings outlook was reduced. The August 6, 2026 update lowered full-year revenue guidance to $2.52–2.60 billion and adjusted diluted earnings per share to $0.65–0.90. Management attributed the revision to China demand headwinds and a softer respiratory environment. Guidance update.
• The published structure has failed. The supplied adjusted market series records a September 18, 2026 close of $10.62, below the September 6 dossier’s $13.75 weekly threshold. That is an observed invalidation, regardless of whether a transaction eventually emerges.

Setup & Price Structure

The September 18, 2026 market snapshot shows a $10.62 daily close, a three-month price decline of 14.1%, and a price 70.0% below the supplied $35.38 trailing-year high. The 14-period relative strength index (RSI) is 12.7. These measurements establish weak momentum; they do not establish a reversal or identify who is transacting.

The $13.75 level is the former published thesis threshold, now above the market. The $10.62 level is a newly specified prospective research condition anchored to the September 18 close, not a demonstrated support shelf. A weekly close below $10.62 ends the residual recovery case without changing the recorded failure of the earlier thesis.

Current short interest, securities-lending costs, moving-average distance and a representative retail-attention series are missing. The evidence is insufficient to classify crowding, forced liquidation or squeeze potential. The June 29 sale coverage documents attention around that event; it cannot establish September participation.

Catalyst Calendar (next 30 days)

For September 20–October 20, 2026, no company-confirmed earnings, transaction or regulatory event date was verified. The company’s accessible events page did not establish a dated catalyst within this window.

The next quarterly release remains undated in the verified material. It would test the August 6 guidance reset and whether management can restore a free-cash-flow forecast. A definitive divestiture agreement is also unscheduled; the June 27 reported process supplies no completion deadline. Neither event can be treated as an imminent catalyst.

What Would Change Our Mind

The former rumor-supported structure is already broken: September 18’s $10.62 close breached the previously published $13.75 weekly condition. A new agreement disclosing cash consideration, closing conditions and intended debt repayment, accompanied by a weekly close above $13.75, would establish the specified recovery outcome.

Further deterioration would end that prospective case through a weekly close below $10.62. Separately, a company announcement terminating the divestiture process would remove its transaction premise. Another reduction below the August 6 revenue-guidance range would undermine the operating recovery argument even if transaction discussions continued.

Correlation Notes

This remains a single-company situation. The supplied September 18 snapshot contains no peer-return series or measured correlations, so it supports no claim that a diagnostics-sector move explains QDEL’s decline. The relevant documented exposures are company-specific: the June sale report and the China and respiratory demand headwinds identified in the August 6 results. No semiconductor-equipment or cryptocurrency linkage is established by that evidence.